A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants. Kim DG, Kim U, Park IH, Ryu B, et al. Antiviral Res 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.

Read + Share

Amedeo Smart

Independent Medical Education

Kim DG, Kim U, Park IH, Ryu B, et al. A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants. Antiviral Res 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.
PMID: 37944822